Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Jun 13 04:00PM ET
0.2919
Dollar change
-0.0212
Percentage change
-6.77
%
Index- P/E- EPS (ttm)-4.92 Insider Own2.73% Shs Outstand29.01M Perf Week1.50%
Market Cap8.47M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float28.22M Perf Month30.90%
Income-19.38M PEG- EPS next Q- Inst Own1.46% Short Float8.81% Perf Quarter-19.65%
Sales0.00M P/S- EPS this Y- Inst Trans18.02% Short Ratio0.54 Perf Half Y-71.66%
Book/sh0.16 P/B1.82 EPS next Y- ROA-205.73% Short Interest2.49M Perf Year-88.46%
Cash/sh0.12 P/C2.44 EPS next 5Y- ROE-302.69% 52W Range0.22 - 3.97 Perf YTD-65.72%
Dividend Est.- P/FCF- EPS past 5Y27.47% ROIC-501.16% 52W High-92.65% Beta-0.40
Dividend TTM- Quick Ratio1.94 Sales past 5Y- Gross Margin- 52W Low35.77% ATR (14)0.04
Dividend Ex-Date- Current Ratio1.94 EPS Y/Y TTM74.34% Oper. Margin- RSI (14)49.80 Volatility4.80% 6.45%
Employees15 Debt/Eq0.00 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.50
Option/ShortNo / Yes LT Debt/Eq0.00 EPS Q/Q92.96% Payout- Rel Volume0.16 Prev Close0.31
Sales Surprise- EPS Surprise0.00% Sales Q/Q- Earnings- Avg Volume4.63M Price0.29
SMA200.20% SMA503.37% SMA200-55.93% Trades Volume757,545 Change-6.77%
Date Action Analyst Rating Change Price Target Change
Jan-26-21Initiated National Securities Buy $7
Apr-29-19Initiated Noble Capital Markets Outperform $5
Jun-03-25 07:00AM
May-29-25 07:00AM
May-28-25 07:00AM
May-07-25 07:00AM
May-06-25 07:00AM
07:30AM Loading…
Apr-30-25 07:30AM
Apr-29-25 07:30AM
Apr-28-25 07:30AM
Apr-24-25 08:15AM
Apr-22-25 08:15AM
Mar-26-25 08:15AM
Mar-25-25 08:15AM
Mar-04-25 08:15AM
Feb-19-25 08:15AM
Feb-18-25 08:15AM
08:15AM Loading…
Feb-13-25 08:15AM
Jan-24-25 07:28AM
Jan-23-25 08:00AM
Jan-14-25 09:28AM
Jan-06-25 09:15AM
Dec-16-24 09:15AM
Nov-21-24 10:16AM
Nov-20-24 09:29AM
Nov-05-24 09:29AM
Oct-31-24 09:29AM
Oct-28-24 09:29AM
Oct-24-24 09:29AM
Oct-16-24 07:45AM
Oct-15-24 09:29AM
Oct-10-24 09:29AM
09:29AM Loading…
Oct-07-24 09:29AM
Sep-23-24 09:29AM
Sep-19-24 09:29AM
Sep-09-24 09:29AM
Sep-04-24 09:29AM
Sep-03-24 08:15AM
Aug-15-24 09:30AM
Aug-14-24 09:25AM
Aug-13-24 08:31AM
Aug-08-24 08:30AM
Jun-27-24 08:31AM
May-30-24 08:31AM
May-20-24 12:53PM
May-15-24 04:42AM
May-14-24 08:31AM
May-13-24 08:31AM
May-08-24 06:08PM
May-07-24 09:15AM
May-01-24 08:31AM
Apr-09-24 08:31AM
Apr-04-24 08:57AM
Apr-03-24 08:31AM
Apr-02-24 08:31AM
Mar-22-24 04:10PM
Mar-19-24 01:24PM
Mar-12-24 09:01AM
Mar-06-24 08:30AM
Feb-07-24 08:15AM
Feb-06-24 07:30AM
Feb-05-24 07:30AM
Jan-31-24 08:42AM
Jan-05-24 07:00AM
Nov-23-23 08:30AM
Nov-03-23 09:00AM
Nov-01-23 07:30AM
Oct-20-23 03:00PM
07:30AM
Oct-06-23 09:00AM
Oct-04-23 12:00PM
Sep-21-23 08:30AM
Sep-19-23 09:00AM
Sep-08-23 08:00PM
Sep-07-23 07:30AM
Sep-04-23 12:00PM
Sep-01-23 09:20PM
Aug-31-23 12:44AM
Aug-24-23 12:25AM
Aug-23-23 02:06AM
Aug-22-23 07:30AM
Aug-13-23 10:24AM
Aug-10-23 07:30AM
Aug-08-23 01:04AM
Jul-28-23 08:00PM
Jul-25-23 01:22AM
Jul-21-23 04:15PM
12:57AM
Jul-20-23 01:05AM
Jul-19-23 08:00AM
12:37AM
Jul-18-23 08:37AM
Jul-12-23 01:00AM
Jul-07-23 09:00PM
Jul-06-23 08:17AM
12:51AM
Jul-05-23 08:35AM
Jun-29-23 09:03PM
Jun-28-23 08:35AM
Jun-02-23 10:15AM
Jun-01-23 11:59AM
May-31-23 12:59AM
Genprex, Inc. is a clinical-stage gene therapy company, which engages in the development of therapies for patients with cancer and diabetes. The company product is REQORSA immunogen therapy drug for non-small cell lung cancer. Its other technologies include GPX-002 gene therapy for diabetes, and ONCOPREX nanoparticle delivery system. Genprex was founded by J. Rodney Varner on April 1, 2009 and is headquartered in Austin, TX.